Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 4.84 -0.05 (-0.92%)
price chart
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sells Marketing And Distribution ...
Dallas, Texas 07/22/2014 (ustradevoice) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s wholly owned subsidiary Arena Pharmaceuticals GmbH has undertaken a marketing and supply deal for BELVIQ� with Abic Marketing Limited, the local Israel-based ...
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ ...  Wall Street Journal
Arena Pharmaceuticals to Market and Supply BELVIQ in Israel  Pharmaceutical Processing
Related articles »  
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks.
Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today
NEW YORK (TheStreet) -- Arena Pharmaceuticals (ARNA_) shares are plummeting, down -8.1% to $5.37, on Monday after CEO Jack Lief sold 223,525 shares of the company at an average price $5.85 for a total transaction of $1,307,621.25, according to an ...
Arena Stock Takes A Tumble � CEO Sells Shares, Investor Confidence Falls  Bidness Etc
Arena chief's stock sale invites criticism (ARNA)  Seeking Alpha
Related articles »  
How Biotech Stocks React on News- Arena Pharmaceuticals, Inc. (NASDAQ ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -1.41%, closing the day at $4.88 in last regular trading while in after hours trading shares moved up 2.05%.
News Recap: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Geron Corporation ...  Market News Call
Related articles »  
Eye-Catching Stocks � Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), EXCO ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) decreased -0.58% at the price of $4.85 recently on a traded volume of 1.84 million shares, in comparison to 5.63 million shares of average trading volume.
Morning Alert-Arena Pharmaceuticals, Inc. (Nasdaq :ARNA) ,Ariad ...
Las Vegas, NV - July 22, 2014 - (TechSonian) �Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) declared that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens.
Related articles »  
News Recap: MannKind Corporation (NASDAQ:MNKD), Geron Corporation ...
... issues news alert on MannKind Corporation (NASDAQ:MNKD), Geron Corporation (NASDAQ:GERN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). MannKind Corporation (NASDAQ:MNKD)'s shares dropped 1.73% to $9.63. The company on June 28 ...
News Recap-Newcastle Investment Corp. (NYSE:NCT),Arena Pharmaceuticals ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ� (lorcaserin HCl) with Teva Pharmaceutical Industries ...
Related articles »  
Arena Gives Pipeline Exposure - Is The Company Partner Shopping? (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) has announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators" by the United States Patent and Trademark Office, for APD371, an agonist of the cannabinoid receptor 2 ...
Arena Pharmaceuticals Pain Candidate Gets New U.S. Patent  Zacks.com
Morning Alert - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Achillion ...  Techsonian (press release)
Related articles »  
Big Movers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc ...
VIVUS, Inc. (NASDAQ:VVUS) on 12 June announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis. On last ...